Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.

Abstract: Formulations comprising anionic agents such as nucleic acids within a lipid-containing particle methods of formulating a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for preparing a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for therapeutic delivery of an anionic agent to a patient in need thereof, where the anionic agent is formulated in a lipid-containing particle as described herein.

Abstract: The present invention provides a method for removing a tattoo in a region of skin the method comprises administering to a least a portion of the tattoo a composition comprising an effective amount of a bisphosphonate and at least one pharmaceutically acceptable excipient to at least cause fading of the tattoo in said region.

Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

Abstract: The present invention provides a composition for inhibiting proliferation of a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative, which contains a fatty acid having 18 carbon atoms and a hydroxyl group at the 10-position as an active ingredient. Furthermore, the present invention provides a composition for preventing or treating a disease caused by a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative.

Abstract: Given its various activities in the brain, nitric oxide (NO) has been associated with various neuropsychiatric diseases and/or neuropsychiatric disorders, including schizophrenia. In fact, evidence has been accumulating to show that abnormalities in NO levels are associated with schizophrenia. Among a number of NO's neural mechanisms associated with schizophrenia, its role as a second messenger of NMDA receptor activation, which interacts with both dopaminergic and serotonergic pathways, has been of particular focus. It demonstrated herein that a combined administration of nitric oxide synthase substrates and co-factors display antineuropsychiatric activity and cognitive benefit by re-establishing homeostatic nitric oxide production.

Abstract: Hyperstable liposome comprising an anti-mitotic agent, one or more anions and one or more cations entrapped in the inner milieu, wherein the entrapped anti-mitotic drug is released at a slow rate that is less than 0.6% in 12 hours or less than 5% in 8 hours when the liposomes are suspended in 600 mM sucrose. These liposomes are useful in the treatment of cancer. In particular, HEPC:Chol:DSPE-PEG2000 (50:45:5) liposomes comprising BI 2536 and citrate:phosphate in a ratio of 1:3.

Abstract: A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.

Abstract: The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.

Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases and cancers.

Abstract: Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.

Abstract: Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.

Abstract: Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.

Abstract: The present invention relates to a peptide exhibiting physiological activities and a composition including the peptide. Because the peptide of the present invention exhibits various physiological activities such as muscle relaxation, skin wrinkle improvement, sebum production suppression, and the like, the peptide may be used as an active ingredient in a pharmaceutical composition for muscle relaxation, or cosmetics for improving skin wrinkles, suppressing sebum production, or ameliorating acne.

Abstract: The present invention is directed to a liposomal formulation having a lipid ingredient encapsulating fluticasone furoate, and a method for preparing the liposomal formulation. The liposome formulation comprises a lipid and a sterol. The method of preparing the liposomes comprises the steps of (1) mixing fluticasone furoate with lipid ingredients comprising a lipid and a sterol, (2) injecting the mixture into normal saline solution, and (3) ultrafiltering and concentrating the resulting solution. This preparation method can produce a liposome formulation having desirable properties and compositions, for example, the ratio of the lipid ingredient, the drug to lipid ratio, and the pH value, which is suitable for nebulization inhalation.

Abstract: The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same. The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.

Abstract: The present invention provides novel antigens of an allergy to a quail egg, methods and kits for diagnosing an allergy to a quail egg, pharmaceutical compositions comprising such an antigen, and quail eggs or processed products of quail egg which are devoid of such an antigen.

Abstract: The present invention relates to compositions of perillic acid compounds, therapeutic and non-therapeutic uses of the compounds and compositions as well as a method of preparing the composition.

Abstract: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

Abstract: The described invention provides methods for treating pulmonary cancer in a subject, by administering to the subject by inhalation a composition of inhalational lipid cisplatin (ILC) comprising a lipid-complexed cisplatin.

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.

Abstract: Disclosed herein are poly(hydroxylalkyleneimine disulfide)polymers, which have both desirable transfection properties and reduced toxicity.

Abstract: Presented herein are compositions comprising L-serine, or a precursor, derivative or conjugate thereof, and a non-toxic metal, such as zinc. Compositions disclosed herein can be used for the prevention and treatment of neurodegenerative diseases, or related symptoms thereof.

Abstract: A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided.

Abstract: The present invention provides an immunity induction-promoting composition which has a track record of use as a medicine or medicinal additive and is capable of safely and effectively inducing cellular immune response, and a vaccine pharmaceutical composition containing the immunity induction-promoting composition. The present invention relates to an immunity induction-promoting composition containing an immunity induction promoter whose active ingredient is an antimicrobial drug.

Abstract: The present invention relates to a test support method which is a means for predicting whether or not pathological complete response (pCR) will be attained when a preoperative chemotherapy with an anticancer drug is performed, the method using a sample (breast cancer tissue section) collected from a breast cancer patient to be subjected to the preoperative chemotherapy. The test support method includes: [1] the step of acquiring a fluorescence image of a breast cancer tissue section, which fluorescence image shows bright spots of fluorescent nanoparticles labeling one or more kinds of breast cancer-related proteins; [2] the step of acquiring at least one index relating to the expression level(s) of the breast cancer-related protein(s) on the basis of the bright spots of the fluorescence image; and [3] the step of acquiring information for predicting pCR by performing an analysis using the above-described at least one index.

Abstract: Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).

Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.

Abstract: Non-vesicular nanoparticles which have antibacterial activity and are made from a C8-C28 fatty acid or a derivative thereof, a surfactant and an optional lipid.

Abstract: An object of the present invention is to provide a microneedle array which is capable of suppressing aggregation of liposomes in a case where a water-soluble polymer is mixed with liposomes during production of the microneedle array and is capable of localizing a drug at a tip of a needle. According to the present invention, provided is a microneedle array including: a sheet; and a plurality of needles which are present on an upper surface of the sheet, in which each needle contains a water-soluble polymer, a drug, a liposome, and a salt, a zeta potential of the liposome is ?10 mV or less, the zeta potential is a zeta potential of a liquid obtained by diluting the liposome to 0.1 mg/mL with 10 mmol/L of a phosphoric acid aqueous solution having a pH of 7, and a content of the salt in a portion of each needle which contains the liposome is 2.5 mmol/g or less.

Abstract: The invention relates to an emulsion for the topical treatment of dermal infections and mucosal infections, in particular of urogenital infectious diseases, characterized in that an antimicrobial agent and an anti-adhesive agent, preferably an NSAID, are used in combination.

Abstract: Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of CBD to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

Abstract: The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).

Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.

Abstract: The present invention includes compounds, compositions and methods for treating and/or preventing chlorine inhalation toxicity and/or injury in a subject subjected to chlorine inhalation.

Abstract: The invention relates to a composition comprising: (i) a trialkylsiloxysilylcarbamoyl pullulan compound, (ii) a polymethyl methacrylate polymer, (iii) a mattifying substance, and (iv) at least one volatile hydrocarbon oil. The invention is also targeted at the use of such a composition for making up and/or caring for keratinous substances, the skin and the lips, and more particularly in mascaras, foundations and lipsticks.

Abstract: Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided.

Abstract: Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.

Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.

Abstract: The disclosure provides for therapies and methods to treat atherosclerosis and/or hyperlipidemia, and complications resulting therefrom, with compositions that comprise therapeutically effective amounts of one or more human milk oligosaccharides.

Abstract: This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment.

Abstract: The present invention relates to an ear-cleansing agent for companion animals and a method of manufacturing the same. More particularly, the present invention relates to an ear-cleansing agent for companion animals, which includes distilled Chamaecyparis obtusa water extracted from Chamaecyparis obtusa trees so as to enable antibacterial action, deodorization, and exfoliation and which does not include a surfactant so that the skin is not irritated even when the ear-cleansing agent is not washed away using water, and a method of manufacturing the same.

Abstract: The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolysed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment of prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in catheter locking solutions and for use in wound care.

Abstract: The invention relates to a composition for dressing cutaneous lesions, in particular cutaneous leishmanial lesions or cutaneous lesions due to actinic keratosis, comprising, based on the total weight of the composition:—10.0 weight percent to 35 weight percent of a one or more diols, selected from the group comprising 1,2-propylene glycol, 1,2-pentanediol, 1,3-butanediol and 2,2?-[Ethane-1,2-diylbis(oxy)]di(ethan-1-ol),—2.0 weight percent to 20 weight percent of at least one first film-forming agent, selected from one or more of a cellulose derivative, hemicellulose, a hemicellulose derivative, chitosan, a chitosan derivative, or oligoglucosamines,—0.2 to 25.0 weight percent of at least one elastic second film-forming agent, selected from one or more thickening agents,—0.2 to 25.0 weight percent of one or more polymeric surfactants,—0.005 to 0.5 weight percent chlorate-free chlorite,—water adding up to 100.0 weight percent.

Abstract: This invention relates to a point of use Hydrogen production unit for use with a Hydrogen fuel cell. The unit uses energy compression to produce a high energy pulse which reacts with the plasma of a gas filled flashlamp to produce a very high pulse of power which is discharged into the water via the surface of the flashlamp to activate the photocatalyst's surface and water interface to produce Hydrogen gas in a water tank or vessel having a gas filled flashlamp or a side emitting fiber optic array. The Hydrogen gas is fed to a storage container and thence to a fuel cell whom it is converted into power to drive vehicles, ships, airplanes, underwater vehicles, boats, etc.

Abstract: The drug-containing fat emulsion of the present invention, which comprises at least a slightly water soluble drug, an oil or fat, an emulsifier, and water as components, is characterized by having a content of the oil or fat of 2 to 120 mg/mL (excluding 2 mg/mL), having a weight ratio of the drug to the oil or fat (drug/(oil or fat)) of 0.001 to 20 (provided that the total content of the drug and the oil or fat is at most 125 mg/mL), having a content of lecithin as the emulsifier of 50 to 200 mg/mL (in which 50% by weight or less of the used lecithin is optionally replaced by an emulsifier other than lecithin), and having a turbidity of 0.5 or lower.

Abstract: A method for manufacturing a negatively charged supported lipid bilayer. The method comprises the steps of preparing a formulation comprising at least three lipids (1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), cholesterol and at least one lipid different from DOPS and cholesterol) dissolved in a first solvent, of evaporating the first solvent, of adding an aqueous formulation of mesoporous silica nanoparticles, of performing an ultra-sonication and of performing a centrifugation. The method is remarkable in that the number of equivalents of cholesterol relative to one equivalent of DOPS is comprised between 2.30 and 2.70. Additionally, negatively charged supported lipid bilayer on a mesoporous silica nanoparticle comprising cholesterol, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) and at least one lipid different from DOPS and cholesterol.

Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.

Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.